{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:15:59Z","timestamp":1777529759546,"version":"3.51.4"},"reference-count":18,"publisher":"Japanese Society of Internal Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2018]]},"DOI":"10.2169\/internalmedicine.9642-17","type":"journal-article","created":{"date-parts":[[2017,12,7]],"date-time":"2017-12-07T17:10:07Z","timestamp":1512666607000},"page":"849-853","source":"Crossref","is-referenced-by-count":8,"title":["A Rare Combination of Dermatomyositis, Interstitial Pneumonia, and Lung Cancer in a Patient Treated with Immunosuppressive Therapy and Chemotherapy"],"prefix":"10.2169","volume":"57","author":[{"given":"Wakako","family":"Daido","sequence":"first","affiliation":[{"name":"Department of Respiratory Disease, Hiroshima Red Cross Hospital & Atomic Bomb Survivors Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Yamasaki","sequence":"additional","affiliation":[{"name":"Department of Respiratory Disease, Hiroshima Red Cross Hospital & Atomic Bomb Survivors Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Morio","sequence":"additional","affiliation":[{"name":"Department of Respiratory Disease, Hiroshima Red Cross Hospital & Atomic Bomb Survivors Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiko","family":"Funaishi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Disease, Hiroshima Red Cross Hospital & Atomic Bomb Survivors Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayaka","family":"Ishiyama","sequence":"additional","affiliation":[{"name":"Department of Respiratory Disease, Hiroshima Red Cross Hospital & Atomic Bomb Survivors Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Deguchi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Disease, Hiroshima Red Cross Hospital & Atomic Bomb Survivors Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Taniwaki","sequence":"additional","affiliation":[{"name":"Department of Respiratory Disease, Hiroshima Red Cross Hospital & Atomic Bomb Survivors Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Ohashi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Disease, Hiroshima Red Cross Hospital & Atomic Bomb Survivors Hospital, Japan"},{"name":"Ohashi Clinic, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Hattori","sequence":"additional","affiliation":[{"name":"Department of Molecular and Internal Medicine, Institute of Biomedical and Health Science, Hiroshima University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Bardur S, Bernt L, Olof E, Erik A. Risk of cancer in patients with dermatomyositis or polymyositis. N Eng J Med 326: 363-367, 1992.","DOI":"10.1056\/NEJM199202063260602"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Hidano A, Kaneko K, Arai Y, Kikuchi R. Survey of the prognosis for dermatomyositis, with special reference to its assosiation with malignancy and pulmonary fibrosis. J Dermatol 13: 233, 1986.","DOI":"10.1111\/j.1346-8138.1986.tb02935.x"},{"key":"3","unstructured":"3. Fujita Y, Hirano S, Yoneshima Y, et al. A case of acute exacerbatuin of interstitial pneumionia complicated with dermatomyositis during treatment for lung cancer, and literature review. Nihon Kokyuki Gakkai Zasshi 49: 108-115, 2011 (in Japanese, Abstract in English)."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Takato H, Waseda Y, Watanabe S, et al. Pulmonary manifestations of anti-ARS antibody positive interstitial pneumonia - with or without PM\/DM. Respir Med 107: 128-133, 2013.","DOI":"10.1016\/j.rmed.2012.09.005"},{"key":"5","unstructured":"5. Satoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EK. A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol 52: 1-19, 2017."},{"key":"6","unstructured":"6. Chen D, Yuan S, Wu X, et al. Incidence and predictive factors for malignancies with dermatomyositis: a cohort from southern China. Clin Exp Rheumatol 32: 615-621, 2014."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Wang J, Guo G, Chen G, Wu B, Lu L, Bao L. Meta-analysis of the association of dermatomyositis and polymyositis with cancer. Br J Dermatol 169: 838-847, 2013.","DOI":"10.1111\/bjd.12564"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Antiochos BB, Brown LA, Li Z, Tosteson TD, Wortmann RL, Rigby WF. Malignancy is associated with dermatomyositis but not polymyositis in Northern New England, USA. J Rheumatol 36: 2704-2710, 2009.","DOI":"10.3899\/jrheum.090549"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Nakashima R, Imura Y, Hosono Y, et al. The multicenter study of a new assay for simultaneous detection of multiple anti-aminoacyl-tRNA synthetases in myositis and interstitial pneumonia. PLoS One 9: e85062, 2014.","DOI":"10.1371\/journal.pone.0085062"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Yoshifuji H, Fujii T, Kobayashi S, et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity 39: 233-241, 2006.","DOI":"10.1080\/08916930600622884"},{"key":"11","unstructured":"11. Mimori T. Anti-amimoacyl-tRNA synthetase antibody: a biomarker of myositis and interstitial pneumonia. Jpn J Chest Dis 74: 730-738, 2015."},{"key":"12","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/17401","volume":"397","author":"M Hojo","year":"1999","unstructured":"12. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397: 530-534, 1999.","journal-title":"Nature Cell Biology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-0836","issn-type":"print"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Shihab FS, Bennett WM, Isaac J, Yi H, Andoh TF. Nitric oxide modulates vascular endothelial growth factor and receptors in chronic cyclosporine nephrotoxicity. Kidney Int 63: 522-533, 2003.","DOI":"10.1046\/j.1523-1755.2003.00757.x"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Walz G, Zanker B, Melton LB, Suthanthiran M, Strom TB. Possible association of the immunosuppressive and B cell lymphoma-promoting properties of cyclosporine. Transplantation 49: 191-194, 1990.","DOI":"10.1097\/00007890-199001000-00042"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Minegishi Y, Sudoh J, Kuribayasi H, et al. The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias. Lung Cancer 71: 70-74, 2011.","DOI":"10.1016\/j.lungcan.2010.04.014"},{"key":"16","unstructured":"16. Shukuya T, Ishiwata T, Hara M, et al. Carboplatin plus weekly paclitaxel treatment in non-small cell lung cancer patients with interstitial lung disease. Anticancer Res 30: 4357-4361, 2010."},{"key":"17","unstructured":"17. Sekine A, Satoh H, Tomohisa B, et al. Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study. Cancer Chemother Pharmacol 77: 1245-1252, 2016."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kenmotsu H, Naito T, Kimura M, et al. The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. J Thorac Oncol 6: 1242-1246, 2011.","DOI":"10.1097\/JTO.0b013e318216ee6b"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/6\/57_9642-17\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T13:32:51Z","timestamp":1570455171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/6\/57_9642-17\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9642-17","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}